Published in Pediatr Infect Dis J on October 01, 2012
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatr Infect Dis J (2013) 1.30
Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev (2014) 1.21
Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol (2013) 1.09
Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci (2013) 1.04
Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One (2013) 1.02
Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis (2014) 1.01
Vaccination Drives Changes in Metabolic and Virulence Profiles of Streptococcus pneumoniae. PLoS Pathog (2015) 0.88
Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics (2014) 0.85
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infect Dis Clin North Am (2015) 0.82
Population Structure of Streptococcus pneumoniae Causing Invasive Disease in Adults in Portugal before PCV13 Availability for Adults: 2008-2011. PLoS One (2016) 0.80
Virulence potential and genome-wide characterization of drug resistant Streptococcus pneumoniae clones selected in vivo by the 7-valent pneumococcal conjugate vaccine. PLoS One (2013) 0.78
Characteristics of serogroup 20 S.pneumoniae isolates from Brazil. BMC Infect Dis (2016) 0.75
A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. Cell Chem Biol (2016) 0.75
Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians. Pediatr Infect Dis J (2016) 0.75
How might immunization rates change if cost sharing is eliminated? Public Health Rep (2014) 0.75
Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J (2007) 3.99
Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics (2005) 3.42
Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics (2009) 3.32
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis (2009) 2.36
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J (2009) 2.12
Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis (2006) 1.99
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. Proc Natl Acad Sci U S A (2003) 1.75
Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics (2010) 1.72
Otitis media and its consequences: beyond the earache. Lancet Infect Dis (2010) 1.68
Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J (2010) 1.67
Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J (2012) 1.41
Severity of invasive pneumococcal disease in children caused by susceptible and nonsusceptible isolates. Pediatr Infect Dis J (2014) 1.40
Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine (2009) 1.40
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics (2005) 1.39
Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics (2003) 1.37
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine (2010) 1.37
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. Pediatr Infect Dis J (2011) 1.28
Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect Immun (2006) 1.25
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A (2013) 1.23
Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J (2002) 1.22
A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine (2010) 1.22
Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. Antimicrob Agents Chemother (2002) 1.20
Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Invest (2012) 1.16
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine (2010) 1.12
Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis (2009) 1.11
Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol (2013) 1.09
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J (2014) 1.05
Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution. Clin Infect Dis (2012) 1.01
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine (2009) 1.00
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics (2007) 1.00
Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2009) 0.97
Multiple consecutive lavage samplings reveal greater burden of disease and provide direct access to the nontypeable Haemophilus influenzae biofilm in experimental otitis media. Infect Immun (2007) 0.95
Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J (2011) 0.94
Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine (2005) 0.93
Sialic acid mediated transcriptional modulation of a highly conserved sialometabolism gene cluster in Haemophilus influenzae and its effect on virulence. BMC Microbiol (2010) 0.90
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother (2008) 0.89
Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine (2013) 0.89
Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox. J Infect Dis (2009) 0.89
Recent advances in otitis media. 6. Vaccine. Ann Otol Rhinol Laryngol Suppl (2005) 0.88
Streptococcus pneumoniae clonal complex 199: genetic diversity and tissue-specific virulence. PLoS One (2011) 0.87
Replacement pneumococcal disease in perspective. Clin Infect Dis (2008) 0.87
Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregivers. Pediatr Infect Dis J (2012) 0.86
Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol (2003) 0.85
A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr (2011) 0.82
Formulations for trans-tympanic antibiotic delivery. Biomaterials (2012) 0.81
Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media. Microbes Infect (2012) 0.81
Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines (2003) 0.80
Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: Implications for the conjugate vaccine. Vaccine (2010) 0.80
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. PLoS One (2013) 0.77
Detection of group B streptococcal bacteremia in simulated intrapartum antimicrobial prophylaxis. Diagn Microbiol Infect Dis (2003) 0.77
Conjugate meningococcal vaccines: lifesaving or inefficient use or both-no easy answer. Clin Infect Dis (2010) 0.76
Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS Res Ther (2007) 0.75
Seasonal variation in penicillin susceptibility and invasive pneumococcal disease. Pediatr Infect Dis J (2015) 0.75
Sexually Transmitted Disease Program Evolution in Response to Changes in the Public Health Environment: A Massachusetts Example. Sex Transm Dis (2016) 0.75
Evaluating Quality of Care for Sexually Transmitted Infections in Different Clinical Settings. Sex Transm Dis (2015) 0.75
Getting What You Pay For: The Economics of Quality Care for Sexually Transmitted Infections. Sex Transm Dis (2016) 0.75
Pediatric respiratory tract infections: etiology, microbiology and resistance trends. Introduction. Pediatr Infect Dis J (2003) 0.75
Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy. Pediatr Infect Dis J (2002) 0.75
Clinically based surveillance of invasive meningococcal disease in young children admitted to selected US hospitals between January 2000 and June 2009: a retrospective cohort study. Hum Vaccin Immunother (2012) 0.75
Increasing focus on local epidemiology demonstrates potential value of pneumococcal conjugate vaccines in Middle East and North Africa Region. Vaccine (2012) 0.75
The Value of Experiential Sexually Transmitted Disease Clinical Training in the Digital Age. Sex Transm Dis (2016) 0.75